Drug
Nbi 1070770
Nbi 1070770: highest development phase Phase 2, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-1070770 NCT06267846 | Phase 2 | Major Depressive Disorder |
Latest
No recent events.
Follow Nbi 1070770 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.